deltatrials

Multiple myeloma Trials in Dayton, United States

Conditions / Multiple myeloma / Dayton, United States

Clinical trials for Multiple myeloma investigate a range of treatment strategies and patient populations.

14 total trials for this combination

Showing top 10 of 14 trials

Trials

NCT ID Title Status Phase
NCT00602641 Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma ACTIVE_NOT_RECRUITING
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) ACTIVE_NOT_RECRUITING
NCT00602641 Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma ACTIVE_NOT_RECRUITING
NCT00874211 S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases COMPLETED
NCT00602641 Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma ACTIVE_NOT_RECRUITING
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) ACTIVE_NOT_RECRUITING
NCT00602641 Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma ACTIVE_NOT_RECRUITING
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) ACTIVE_NOT_RECRUITING
NCT00602641 Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma ACTIVE_NOT_RECRUITING
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) ACTIVE_NOT_RECRUITING

Related Pages